Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers
Status:
Active, not recruiting
Trial end date:
2022-05-02
Target enrollment:
Participant gender:
Summary
This is a Phase 1 study evaluating the safety of ABT-263 administered in combination with
rituximab in subjects with CD20-positive lymphoproliferative disorders. The extension portion
of the study will allow active subjects to continue to receive ABT-263 for up to 9 years
after the last subject transitions with quarterly study evaluations.